Canadian consensus statement on the management of radioactive iodine–resistant differentiated thyroid cancer

Author:

Boucher Andrée,Ezzat Shereen,Hotte Sebastien,Rachinsky Irina,Rajaraman Murali,Ruether Dean,Wiseman Sam M.,Brierley James,Ho Cheryl,Krzyzanowska Monika,Lamond Nathan,Massicotte Marie-Hélène,Joseph Shereen,Herscovitch Kassey,Sikora Lindsey,Winquist Eric

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Oral Surgery

Reference49 articles.

1. Canadian cancer statistics 2019;Canadian Cancer Statistics Advisory Committee,2019

2. Refractory thyroid carcinoma: which systemic treatment to use?;Faugeras;Ther Adv Med Oncol,2018

3. Radioiodine refractory differentiated thyroid cancer: Time to update the classifications;Van Nostrand;Thyroid,2018

4. Haddad R, Bischoff L, Busaidy N, et al. Thyroid Carcinoma V1.2019. NCCN Clinical Practice Guidelines in Oncoology (NCCN Guidelines®) March 28, 2019.

5. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer;Schlumberger;N Engl J Med,2015

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3